Introduction
============

A review of epidemiologic studies demonstrates a prevalence of co-morbid depression in a range of 6%--80% of COPD patients, with an average among the majority of the strongest studies of approximately 40%. This compares to a rate of 15% in the general population ([@b61-copd-2-485]; [@b78-copd-2-485]; [@b82-copd-2-485]; [@b9-copd-2-485]; [@b57-copd-2-485]). In cardiac patients the range is 15%--23% ([@b15-copd-2-485]; [@b6-copd-2-485]; [@b84-copd-2-485]) and in cancer patients over a range of 13%--38% ([@b47-copd-2-485]). In a cluster of studies that have compared depressive disorders across diverse chronic illnesses, COPD patients suffer from depression with greater frequency and a greater chronicity of the mood symptoms ([@b58-copd-2-485]; [@b48-copd-2-485]; [@b28-copd-2-485]; [@b22-copd-2-485]). Evidence suggests, however, that the depression experienced by COPD patients is not a homogenous entity. To manage this co-morbidity as effectively as possible it is important to first understand the potential contributors to an individual patient's depression. Chronologically the earliest risk may be a genetic predisposition to depression, followed by the environmental assaults imposed by the respiratory illness itself and finally the direct neuropsychiatric effects of chronic respiratory disease. The goal of this review is to explore each of these elements to help inform clinical management of this patient population.

Genetics
========

In the psychiatric literature the heritability of a vulnerability to depression has been well established. First-degree relatives of individuals with major depression are 2 to 3 times as likely to develop depression when compared to the first-degree relatives of controls. This increased risk is also supported by adoption and twin studies. The latter show a concordance rate of 50% in monozygotic twins, 10%--25% in dizygotic ([@b46-copd-2-485]; [@b75-copd-2-485]; [@b49-copd-2-485]). The age at which this increased risk manifests varies widely from individual to individual, but is often already evident in adolescence ([@b27-copd-2-485]). This vulnerability plays a role in the eventual development of COPD in that adolescents and young adults who are depressed or have a history of depression are more likely to progress in their use of and dependence on nicotine ([@b11-copd-2-485]; [@b30-copd-2-485]; [@b68-copd-2-485]). The genetic underpinning of this vulnerability has recently gained increased support with the finding that the likelihood of an adolescent's smoking progressing from initial nicotine exposure to regular smoking was doubled by each additional copy of an identified allele (DRD2A1) for a subtype of a dopamine receptor. The presence of depressive symptoms magnified the effect ([@b7-copd-2-485]). These data would suggest that smoking interventions that have been implemented in adults -- such as the administration of antidepressants -- might also be useful to help adolescents stop smoking, but there is currently very limited evidence for any effective interventions in this population. Certainly this is an area that warrants further research.

Smoking, COPD and depression are interrelated in a sort of trinity, with depression playing a role in the initiation and maintenance of smoking, smoking leading to the development of COPD and COPD, in turn, contributing to the genesis of depression. Because of depression's role in the development of nicotine dependence, it might also be considered a risk factor for COPD. In adults, continued smoking increases the morbidity and mortality experienced in COPD. A history of either recent or distant depression has been associated with diminished success in smoking cessation, more persistent withdrawal symptoms and an increased likelihood of recurrence of the depression if nicotine is discontinued ([@b20-copd-2-485], [@b21-copd-2-485]; [@b19-copd-2-485]). The application of antidepressant therapy in smokers who endorsed some level of depressive symptoms did increase abstinence rates up to three months out from quit dates ([@b41-copd-2-485]), a finding consistent with previous reports ([@b44-copd-2-485]; [@b39-copd-2-485]; [@b66-copd-2-485]). There is suggestion that the benefits from the application of antidepressants is not exclusively due to the relief of depressive symptoms but potentially because the vulnerability to nicotine dependence and to depression share a common genetic source, possibly one that defines some characteristic of the dopamine pathways ([@b59-copd-2-485]).

The impact of chronic illness
=============================

The responses to the question of why depression arises so frequently in COPD reflect an evolving understanding of the complex relationships between these two disease entities. Early theory held that depression in chronic illness was a "reaction" to the losses imposed by the illness -- an understandable grieving ([@b1-copd-2-485]). Since that time both the reactions and the losses have been more clearly defined. Loss of functionality is a strong mediator of the development of depression in chronic illness, with an attributable risk measured at 34% ([@b24-copd-2-485]). Functional impacts may include decreased mobility, inability to carry out prior occupational activities, shifted roles within the family constellation and decreased ability to physically participate in previously enjoyed recreational activities. Another common insult to self-image that COPD patients struggle with is the use of supplemental oxygen. In fact, this insult often contributes to patients' reluctance to utilize oxygen therapy ([@b25-copd-2-485]). The psychological losses attached to each of these insults are first the loss of the phenomenon itself and secondly of the emotional or material benefits derived from it.

A second factor in a patient's ability to adjust to the burden of illness is the patency of internal coping mechanisms including self-efficacy and sense of mastery. The stronger patients' sense of mastery or ability to impact the daily experience of their illness, the lower is their risk for depression ([@b13-copd-2-485], [@b42-copd-2-485]). In a cohort of 208 severe COPD patients their level of perceived self-efficacy and functionality had a greater impact on variability in perceived quality of life than either objective or subjective pulmonary function ([@b51-copd-2-485]).

A third influence on a patient's resilience in the face of the stress of dealing with a chronic illness is their perceived level of social support. Overall the greater the level of perceived social support the less likely a patient will report symptoms of depression ([@b64-copd-2-485]). In a study of 719 elderly individuals with a variety of chronic medical issues both strong social supports and effective personal coping strategies were associated with favorable effects in reducing levels of depression. In addition, for the 280 subjects in this study with lung disease (asthma, chronic bronchitis or emphysema), "diffuse" relationships, those that were defined as less intimate, community-based relationships, were helpful in "buffering" the negative effects of the illness ([@b70-copd-2-485]). Associated with higher reports of depressive symptoms across all groups was patients' receipt of "instrumental support" -- tangible assistance with disease management. The suggested interpretation is that receiving high levels of instrumental support reinforces feelings of dependence and helplessness, countermanding feelings of self-efficacy and mastery ([@b69-copd-2-485]). A single study focusing on determinants of depression in COPD patients found that the risk of depression was significantly increased for subjects who lived alone, who had poor reversibility of FEV~1~ on spirometry and those who suffered severe functional impairment ([@b79-copd-2-485]).

These studies suggest that educating patients and caregivers in strategies that maximize independence, encouraging patients to develop and nurture their support systems and to participate in effective rehabilitation can help with both the physical and the psychosocial aspects of COPD. Certainly COPD can impose staggering losses on COPD patients and many of these same losses occur in other chronic illnesses, yet COPD patients demonstrate higher rates of depression. The explanations for this disparity include the early vulnerability posited by genetics studies and the longitudinal physiologic effects of chronic respiratory disease.

COPD effects on the CNS
=======================

Magnetic resonance imaging (MRI) is a non-radiological imaging technique that offers detailed study of soft tissues. In the T2-weighted MRI scans CSF and other areas of acute anoxia or elevated fluid content, such as that seen with edema, appear white. These sites of increased signal are termed hyperintensities ([@b83-copd-2-485]). Multiple studies have noted an increased prevalence of these hyperintensities in subcortical areas in the brains of elderly subjects, collectively called subcortical hyperintensities (SH). The concentration of these subcortical lesions increases with advancing age but they are not universally associated with clinical pathology, appearing in imaging studies of both clinically compromised and healthy elderly subjects ([@b37-copd-2-485]; [@b38-copd-2-485]). When present, SH are typically seen in the deep white matter, periventricular areas, the basal ganglia, the thalamus and the pons. These areas are particularly vulnerable to vascular insult because they are in identified "watershed" or border zones of vascular supply. Considering all sites, the odds-ratio of finding SH increases by approximately 5% per additional year of age ([@b18-copd-2-485]). While the lesions are seen in individuals without clinical disease, the prevalence and severity of SH do increase with cardiovascular risk factors as well as with a high burden of medical co-morbidity ([@b8-copd-2-485]; [@b12-copd-2-485]). The differential diagnosis for the lesions includes malignancies, infarcts and multiple sclerosis as well as less clinically apparent, although still pernicious, conditions typically associated with aging. These include arteriosclerosis and the diminution of autoregulation of blood pressure and subsequent aberrations in blood flow ([@b14-copd-2-485]). In the absence of identified cerebrovascular disease, other factors that have been associated with greater SH burden on MRI include clinically silent stroke, elevated systolic blood pressure and lower forced expiratory volume in 1 second (FEV~1~). When these factors are controlled for, smoking also emerges in positive association with SH ([@b62-copd-2-485]).

Several studies have found that the concentration of SH is also elevated in elderly patients with depression, with an even higher prevalence among the subset of patients whose depression developed after their 5th decade ([@b53-copd-2-485], [@b56-copd-2-485]; [@b33-copd-2-485]; [@b17-copd-2-485]; [@b43-copd-2-485]; [@b60-copd-2-485]). In a meta-analysis a common odds ratio of 3.2 (95% CI 2.11--4.82) was found for the presence of SH in all patients with major depression ([@b80-copd-2-485]). While not consistent across studies, there is some evidence that when compared to individuals who developed depression prior to 40 years of age, a higher concentration of SH is seen in older depressed subjects ([@b73-copd-2-485]).

The concept of "vascular depression" was developed as a putative explanation for elders' increased vulnerability to depression. Evidence supporting the concept includes literature showing that cerebrovascular disease often predates the onset of the depression; the increased prevalence of depression in individuals who also suffer from hypertension or coronary artery disease; and an increased finding of depressive symptoms in patients with vascular dementia when compared to those with non-vascular Alzheimer's disease. Accumulating MRI evidence that shows a high concentration of SH in elderly, depressed patients, and the localization of those lesions in areas at increased risk for vascular compromise, strengthen the argument ([@b2-copd-2-485], [@b3-copd-2-485]). Contrasting studies in late onset depression have found a smaller association with SH but a stronger one with decreased total brain volume, preserving the concept of structural damage albeit with a different manifestation ([@b72-copd-2-485]).

Attempts have been made to identify a constellation of clinical factors that help with the identification of late-onset depression. Late-onset depression has been found to be more refractory to treatment with antidepressants ([@b16-copd-2-485]; [@b40-copd-2-485]), associated with a greater degree of patient apathy ([@b55-copd-2-485]) and less often associated with a family history of depression ([@b35-copd-2-485]; [@b54-copd-2-485]). Additionally, patients are less likely to achieve and sustain remission of their depressed symptoms ([@b35-copd-2-485]; [@b76-copd-2-485]). Relevant to clinical management, the concentration of SH has been associated with more problematic side effects in response to somatic treatments including delirium and parkinsonism with medications and ECT ([@b31-copd-2-485]; [@b32-copd-2-485]; [@b36-copd-2-485]).

There is strong evidence of an association between SH and late-onset depression, as well as between COPD and an increased severity of SH ([@b77-copd-2-485]). A portion of this increase may be accounted for by the subjects' smoking history. Smoking has been shown to be cytotoxic to endothelial cells and, as is discussed further below, this intravascular damage is a likely contributor to the observed SH ([@b10-copd-2-485]). Smoking has also been shown to increase the risk for permanent brain injury following exposure to what might, in the absence of a smoking history, have been a transient ischemic insult ([@b81-copd-2-485]). The fundamental insult in ischemia is a failure to deliver sufficient oxygen to the site of involvement and that insufficiency can be caused by either hypoperfusion or hypoxemia. By the very nature of the disease process COPD is associated with chronic, if often subclinical, hypoxemia. The consequences of chronic hypoxemia include both impaired cognitive function and depression, although the evidence supporting the latter is less robust ([@b26-copd-2-485]; [@b67-copd-2-485]). In a comparison of cognitive function between healthy subjects, COPD patients and patients with Alzheimer's disease (AD) with mild hypoxemia the AD patients had the worst performance, with the COPD patients showing significant impairment relative to the normals ([@b52-copd-2-485]). Imaging studies demonstrate that worse hypoxemia in COPD is associated with decreased perfusion of anterior cortical and subcortical areas and decreased performance on cognitive testing relative to normals ([@b5-copd-2-485]). Most studies of hypoxemia and depression arise from the sleep apnea literature where one of the primary identified sequelae of recurrent nocturnal hypoxemia is depressed mood ([@b4-copd-2-485]).

It should be noted that depression itself has been identified as a risk factor for cerebrovascular insult, and so may contribute to the formation of lesions manifesting as SH. The severity of depressive symptoms is predictive of stroke after controlling for a host of variables including measured blood pressure ([@b74-copd-2-485]), smoking, body mass index, hypertension or diabetes ([@b29-copd-2-485]). A large, longitudinal study of 6095 stroke-free individuals followed for an average of 16 years found that after adjusting for multiple previously identified risks for stroke (age, gender, ethnicity, systolic blood pressure, alcohol use, serum cholesterol level, diabetes and heart disease) being in the top third of measured depression levels increased the risk of stroke over the duration of the study period by 50%--106% when compared to subjects in the lowest third. The relative risk for stroke due to depression was roughly equivalent to a 40-point increase in systolic blood pressure ([@b45-copd-2-485]).

Finally, there is growing evidence that depression and COPD impose similar microvascular and biochemical insults that would be expected to contribute to the accumulation of SH. Both depression and chronic respiratory disease have been associated with processes that jeopardize the microvasculature of the brain. In depression this has been evidenced by significantly elevated biomarkers of oxidative damage. Levels of 8-hydroxy-2′-deoxyguanosine were directly correlated with the severity of the depression and with the level of the resultant oxidative damage was correlated with the chronicity of the depression ([@b34-copd-2-485]). Oxidative stress has also been associated with biochemical alterations in the cell membrane and function of erythrocytes in patients with mental illness. These cell membrane aberrations are thought to interfere with effective transduction of neurotransmitter signaling ([@b71-copd-2-485]). In a treatment study depressed patients were noted to have deranged oxidant and antioxidant defense systems at baseline. After treatment with antidepressants depression measures improved and oxidative stress was reduced ([@b50-copd-2-485]).

In both COPD and depression there is evidence for increased platelet activation that may potentially lead to thrombotic insult to the microvasculature, the type of injury to which the narrow perforating arteries of the brain are particularly vulnerable. In COPD the synthesis of a marker of platelet activation was significantly elevated and inversely related to arterial oxygen tension ([@b23-copd-2-485]). In a comparison of depressed patients and controls, the patients demonstrated increased platelet activation at baseline as well as increased platelet reactivity ([@b65-copd-2-485]). In a small study of depressed patients treatment with the antidepressant sertraline diminished a pre-treatment elevation in platelet activation ([@b63-copd-2-485]).

Conclusion
==========

COPD is a chronic, progressive disease and as such exerts an escalating burden over time. As the size of the elderly population grows, the number of people suffering with this debilitating disease is certain to increase. In spite of the high prevalence of COPD, treatment continues to be primarily symptomatic and rates of functional impairment and mortality have not significantly decreased in the past several decades. While our understanding of the disease continues to progress, our ability to halt, or better still reverse, the progression of the disease has not. Improved management of morbidity must then become a parallel goal and one of the areas with the greatest potential for improvement is the management of patients' co-morbid depression. Depression in COPD is a heterogeneous entity with a potentially composite etiology including genetic predisposition, environmental losses and stressors, as well as direct damage to the brain mediated by the physiologic effects of chronic respiratory illness. As such, the relationships between depression, COPD and smoking are not linear but, rather, interconnected with each element influencing the others to different degrees in any given patient at any given time. Over the course of their lifetimes COPD patients may have experienced multiple exposures that increase their risk for the development of depression. The advantage to recognizing the inter-dependent relationship of these contributing factors is the corollary recognition that effective intervention in any one of them will have a cascading, positive impact on the others. Effectively targeting depression, or lost functionality or chronic hypoxemia will decrease morbidity in that dimension, and potentially in the others as well. There is much research that remains to be done to delineate what the most effective interventions are, but they are progressing. As noted above, identification of direct genetic influences opens the door for early intervention in juvenile vulnerability to nicotine addiction. Research into improved rehabilitation efforts, and a clarification of the best use and format of oxygen supplementation is ongoing with an eye to both decreased physiologic morbidity and increased functionality. At the same time patients are learning self-advocacy and developing support groups to share information and increase their sense of community. Lastly, we continue to search for the best ways to manage depression in patients with COPD. The likely answer will be a combination of psychopharmacology and psychotherapy, but in view of the often refractory nature of the depression there is also a role for electroconvulsive therapy in this population. This developing armamentarium can then be customized to the unique constellation of contributing factors active for a given patient at a given time.
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